|
| 37248394 | Limiting mitochondrial plasticity by targeting DRP1 induces metabolic reprogramming and reduces breast cancer brain metastases. | | 2023 |
| 36396775 | Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ERâ¿¿+â¿¿breast cancer. | Breast Cancer Research and Treatment | 2023 |
| 37608772 | Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer | J Pathol | 2023 |
| 37608771 | Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. | J Pathol | 2023 |
| 38095878 | Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. | | 2023 |
| 37791898 | NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 34986341 | Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. | | 2022 |
| 36304942 | Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer. | Cancer Res Commun | 2022 |
| 36083147 | FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. | Appl Immunohistochem Mol Morphol | 2022 |
| 35561311 | Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. | Cancer Immunol Res | 2022 |
| 34707136 | Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. | Nature Communications | 2021 |
| 34011560 | Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER<sup>+</sup> Breast Cancer. | Clin Cancer Res | 2021 |
| 33529175 | Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. | J Clin Invest | 2021 |
| 33839362 | Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. | Journal of Thoracic Oncology | 2021 |
| 34315849 | Tissue-specific expression of p73 and p63 isoforms in human tissues. | Cell Death and Disease | 2021 |
| 34315723 | Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. | Clin Cancer Res | 2021 |
| 34725325 | Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. | Nat Commun | 2021 |
| 32511636 | Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer. | | 2020 |
| 32129476 | The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. | J Pathol | 2020 |
| 32049049 | Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. | Cancer Cell | 2020 |
| 31822498 | TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. | Clinical Cancer Research | 2020 |
| 31978326 | Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. | Cancer Cell | 2020 |
| 32826327 | Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. | Clin Cancer Res | 2020 |
| 33127913 | Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. | Nat Commun | 2020 |
| 30770369 | Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. | Cancer Res | 2019 |
| 31552290 | PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. | NPJ Breast Cancer | 2019 |
| 30314968 | Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. | Clin Cancer Res | 2019 |
| 30413412 | Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. | Cancer Research | 2019 |
| 30274983 | Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER/HER2 Breast Cancers: Implications to the ExteNET Trial. | Clinical Cancer Research | 2019 |
| 31186280 | Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. | Molecular Cancer Research | 2019 |
| 30914635 | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. | Nat Commun | 2019 |
| 31332390 | A case report of clonal EBV-like memory CD4<sup>+</sup> T cell activation in fatal checkpoint inhibitor-induced encephalitis. | Nat Med | 2019 |
| 30770493 | Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. | Clinical Cancer Research | 2019 |
| 29110314 | Post-irradiation morphoea of the breast: a case report and review of the literature. | Histopathology | 2018 |
| 30224377 | Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers. | Cancer Res | 2018 |
| 29872580 | Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. | OncoImmunology | 2018 |
| 29358172 | Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. | Cancer Res | 2018 |
| 29339738 | DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. | Nature Communications | 2018 |
| 28249908 | Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. | Cancer Res | 2017 |
| 29059433 | An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. | Journal of the National Cancer Institute | 2017 |
| 28794284 | Genomic profiling of ER<sup>+</sup> breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. | Sci Transl Med | 2017 |
| 28416578 | WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanoma. | Molecular and Cellular Proteomics | 2017 |
| 28381415 | HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. | Clinical Cancer Research | 2017 |
| 28546465 | Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. | Molecular and Cellular Proteomics | 2017 |
| 28777142 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. | Adv Anat Pathol | 2017 |
| 28777143 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. | Adv Anat Pathol | 2017 |